You are here:

Valsartan 40mg, 80mg and 160mg capsules and tablets (Diovan®)


Following a full submission.

Valsartan (Diovan) is accepted for restricted use within NHS Scotland to improve survival following myocardial infarction (MI) in clinically stable patients with signs, symptoms or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.

Valsartan has been shown to be as effective as the ACE inhibitor, captopril, in this patient population and should be considered a second-line alternative in patients who cannot tolerate an ACE inhibitor. The economic evaluation demonstrates that valsartan is only cost-effective in the patient population that is intolerant of ACE inhibitors.

Drug Details

Drug Name: Valsartan 40mg, 80mg and 160mg capsules and tablets (Diovan®)
SMC Drug ID: 162/05
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Left ventricular failure and/or left ventricular systolic dysfunction
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Restricted
Date Advice Published: 9 May 2005